(Q39694616)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Gatekeeper mutations mediate resistance to BRAF-targeted therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Richard Marais

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Alfonso Zambon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Neus Cantariño

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Caroline J Springer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Ruth Kirk

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Robert Hayward

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Amaya Viros

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Annette Affolter

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Arnaud Nourry

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Dan Niculescu-Duvaz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

1 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

Science Translational Medicine

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

35ra41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538618%20AND%20SRC:MED&resulttype=core&format=json

Targeting cancer with small molecule kinase inhibitors

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Melanoma biology and new targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

The RAF proteins take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

V599EB-RAF is an oncogene in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellul

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Sorafenib for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Is B-Raf a good therapeutic target for melanoma and other malignancies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Rational design of inhibitors that bind to inactive kinase conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Development and testing of a general amber force field

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Development and validation of a genetic algorithm for flexible docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758

Oncogenic Braf induces melanocyte senescence and melanoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000758